Overview

Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers

Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety, tolerability and pharmacokinetics of single and multiple doses of NNI-362 in healthy aged population.
Phase:
Phase 1
Details
Lead Sponsor:
Neuronascent, Inc.
Collaborator:
National Institute on Aging (NIA)